286 related articles for article (PubMed ID: 25844758)
1. Kidney-type glutaminase (GLS1) is a biomarker for pathologic diagnosis and prognosis of hepatocellular carcinoma.
Yu D; Shi X; Meng G; Chen J; Yan C; Jiang Y; Wei J; Ding Y
Oncotarget; 2015 Apr; 6(10):7619-31. PubMed ID: 25844758
[TBL] [Abstract][Full Text] [Related]
2. Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathway.
Li B; Cao Y; Meng G; Qian L; Xu T; Yan C; Luo O; Wang S; Wei J; Ding Y; Yu D
EBioMedicine; 2019 Jan; 39():239-254. PubMed ID: 30555042
[TBL] [Abstract][Full Text] [Related]
3. Kidney-type glutaminase is a biomarker for the diagnosis and prognosis of hepatocellular carcinoma: a prospective study.
Zhang L; Su K; Liu Q; Li B; Wang Y; Cheng C; Li Y; Xu C; Chen J; Wu H; Zhu M; Mai X; Cao Y; Peng J; Yue Y; Ding Y; Yu D
BMC Cancer; 2023 Nov; 23(1):1081. PubMed ID: 37946141
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial GCN5L1 regulates glutaminase acetylation and hepatocellular carcinoma.
Zhang T; Cui Y; Wu Y; Meng J; Han L; Zhang J; Zhang C; Yang C; Chen L; Bai X; Zhang K; Wu K; Sack MN; Wang L; Zhu L
Clin Transl Med; 2022 May; 12(5):e852. PubMed ID: 35538890
[TBL] [Abstract][Full Text] [Related]
5. Glutaminase 2 negatively regulates the PI3K/AKT signaling and shows tumor suppression activity in human hepatocellular carcinoma.
Liu J; Zhang C; Lin M; Zhu W; Liang Y; Hong X; Zhao Y; Young KH; Hu W; Feng Z
Oncotarget; 2014 May; 5(9):2635-47. PubMed ID: 24797434
[TBL] [Abstract][Full Text] [Related]
6. Glutaminase 2 stabilizes Dicer to repress Snail and metastasis in hepatocellular carcinoma cells.
Kuo TC; Chen CK; Hua KT; Yu P; Lee WJ; Chen MW; Jeng YM; Chien MH; Kuo KT; Hsiao M; Kuo ML
Cancer Lett; 2016 Dec; 383(2):282-294. PubMed ID: 27725225
[TBL] [Abstract][Full Text] [Related]
7. GLS1 promotes proliferation in hepatocellular carcinoma cells via AKT/GSK3β/CyclinD1 pathway.
Xi J; Sun Y; Zhang M; Fa Z; Wan Y; Min Z; Xu H; Xu C; Tang J
Exp Cell Res; 2019 Aug; 381(1):1-9. PubMed ID: 31054856
[TBL] [Abstract][Full Text] [Related]
8. The Expression of Glutaminases and their Association with Clinicopathological Parameters in the Head and Neck Cancers.
Basheer HA; Elsalem L; Salem A; Tailor A; Hunter K; Afarinkia K
Curr Cancer Drug Targets; 2022; 22(2):169-179. PubMed ID: 34951574
[TBL] [Abstract][Full Text] [Related]
9. GLS2 Is a Tumor Suppressor and a Regulator of Ferroptosis in Hepatocellular Carcinoma.
Suzuki S; Venkatesh D; Kanda H; Nakayama A; Hosokawa H; Lee E; Miki T; Stockwell BR; Yokote K; Tanaka T; Prives C
Cancer Res; 2022 Sep; 82(18):3209-3222. PubMed ID: 35895807
[TBL] [Abstract][Full Text] [Related]
10. Glutaminase 2 is a novel negative regulator of small GTPase Rac1 and mediates p53 function in suppressing metastasis.
Zhang C; Liu J; Zhao Y; Yue X; Zhu Y; Wang X; Wu H; Blanco F; Li S; Bhanot G; Haffty BG; Hu W; Feng Z
Elife; 2016 Jan; 5():e10727. PubMed ID: 26751560
[TBL] [Abstract][Full Text] [Related]
11. Decreased STAT4 indicates poor prognosis and enhanced cell proliferation in hepatocellular carcinoma.
Wang G; Chen JH; Qiang Y; Wang DZ; Chen Z
World J Gastroenterol; 2015 Apr; 21(13):3983-93. PubMed ID: 25852285
[TBL] [Abstract][Full Text] [Related]
12. Increased Glutaminolysis Marks Active Scarring in Nonalcoholic Steatohepatitis Progression.
Du K; Chitneni SK; Suzuki A; Wang Y; Henao R; Hyun J; Premont RT; Naggie S; Moylan CA; Bashir MR; Abdelmalek MF; Diehl AM
Cell Mol Gastroenterol Hepatol; 2020; 10(1):1-21. PubMed ID: 31881361
[TBL] [Abstract][Full Text] [Related]
13. The combination of three molecular markers can be a valuable predictive tool for the prognosis of hepatocellular carcinoma patients.
Chen SS; Yu KK; Ling QX; Huang C; Li N; Zheng JM; Bao SX; Cheng Q; Zhu MQ; Chen MQ
Sci Rep; 2016 Apr; 6():24582. PubMed ID: 27079415
[TBL] [Abstract][Full Text] [Related]
14. Nuclear factor-κB p65 regulates glutaminase 1 expression in human hepatocellular carcinoma.
Dong M; Miao L; Zhang F; Li S; Han J; Yu R; Qie S
Onco Targets Ther; 2018; 11():3721-3729. PubMed ID: 29988727
[TBL] [Abstract][Full Text] [Related]
15. High expression of trimethylated histone H3 lysine 4 is associated with poor prognosis in hepatocellular carcinoma.
He C; Xu J; Zhang J; Xie D; Ye H; Xiao Z; Cai M; Xu K; Zeng Y; Li H; Wang J
Hum Pathol; 2012 Sep; 43(9):1425-35. PubMed ID: 22406368
[TBL] [Abstract][Full Text] [Related]
16. High expression of Janus kinase 2 in background normal liver tissue of resected hepatocellular carcinoma is associated with worse prognosis.
Sonohara F; Nomoto S; Inokawa Y; Hishida M; Takano N; Kanda M; Nishikawa Y; Fujii T; Koike M; Sugimoto H; Kodera Y
Oncol Rep; 2015 Feb; 33(2):767-73. PubMed ID: 25420511
[TBL] [Abstract][Full Text] [Related]
17. BCL6B expression in hepatocellular carcinoma and its efficacy in the inhibition of liver damage and fibrogenesis.
Wang W; Huang P; Wu P; Kong R; Xu J; Zhang L; Yang Q; Xie Q; Zhang L; Zhou X; Chen L; Xie H; Zhou L; Zheng S
Oncotarget; 2015 Aug; 6(24):20252-65. PubMed ID: 25970780
[TBL] [Abstract][Full Text] [Related]
18. Long non-coding RNA PANDAR correlates with poor prognosis and promotes tumorigenesis in hepatocellular carcinoma.
Peng W; Fan H
Biomed Pharmacother; 2015 May; 72():113-8. PubMed ID: 26054684
[TBL] [Abstract][Full Text] [Related]
19. Identification of intragenic methylation in the TUSC1 gene as a novel prognostic marker of hepatocellular carcinoma.
Shimizu D; Kanda M; Nomoto S; Oya H; Takami H; Hibino S; Suenaga M; Inokawa Y; Hishida M; Takano N; Nishikawa Y; Yamada S; Fujii T; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
Oncol Rep; 2014 Mar; 31(3):1305-13. PubMed ID: 24366000
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of decreased nidogen-2 expression in the tumor tissue and serum of patients with hepatocellular carcinoma.
Cheng ZX; Huang XH; Wang Q; Chen JS; Zhang LJ; Chen XL
J Surg Oncol; 2012 Jan; 105(1):71-80. PubMed ID: 21815147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
